{"id":"bromfenac-ophthalmic-solution","_fda":{"id":"824d37d0-e25f-4df8-be0e-d9a65046fc10","set_id":"225070ee-d862-4d41-84b8-5bd7a8a03fd7","openfda":{"unii":["8ECV571Y37"],"route":["OPHTHALMIC"],"rxcui":["578018"],"spl_id":["824d37d0-e25f-4df8-be0e-d9a65046fc10"],"brand_name":["Bromfenac Ophthalmic Solution 0.09%"],"spl_set_id":["225070ee-d862-4d41-84b8-5bd7a8a03fd7"],"package_ndc":["62332-508-17"],"product_ndc":["62332-508"],"generic_name":["BROMFENAC OPHTHALMIC SOLUTION 0.09%"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BROMFENAC SODIUM"],"manufacturer_name":["Alembic Pharmaceuticals Inc."],"application_number":["ANDA210560"],"is_original_packager":[true]},"version":"7","pregnancy":["8.1 Pregnancy Teratogenic Effects: Pregnancy Category C . Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post implantation loss. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided."],"description":["11 DESCRIPTION Bromfenac ophthalmic solution 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of bromfenac ophthalmic solution contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodium is designated chemically as sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, with an empirical formula of C 15 H 11 BrNNaO 3 • 3/2 H 2 O. The structural structure for bromfenac sodium is: Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac ophthalmic solution is supplied as a sterile aqueous 0.09% solution, with a pH of 8.3. The osmolality of bromfenac ophthalmic solution is approximately 300 mOsmol/kg. Each mL of bromfenac ophthalmic solution contains: Active : bromfenac sodium hydrate 0.1035% Preservative : benzalkonium chloride (0.05 mg/mL) Inactives : boric acid, disodium edetate (0.2 mg/mL), polysorbate 80 (1.5 mg/mL), povidone K-30 (20 mg/mL), sodium borate, and sodium sulfite anhydrous (2 mg/mL). Sodium hydroxide may be used to adjust pH and water for injection USP. bromfenac-struc"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Bromfenac Ophthalmic Solution 0.09% is supplied in a white LDPE screw neck bottle with a LDPE white nozzle and HDPE gray cap as follows: 1.7 mL in 5 mL container - NDC 62332-508-17 STORAGE: Store at 15° to 25°C (59° to 77°F)"],"geriatric_use":["8.5 Geriatric Use There is no evidence that the efficacy or safety profiles for bromfenac differ in patients 65 years of age and older compared to younger adult patients."],"pediatric_use":["8.4 Pediatric Use Safety and efficacy in pediatric patients below the age of 18 have not been established."],"effective_time":"20250205","nursing_mothers":["8.3 Nursing Mothers Caution should be exercised when bromfenac is administered to a nursing woman."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Ocular Inflammation and Pain Following Cataract Surgery Clinical efficacy was evaluated in three randomized, double-masked, placebo controlled trials in which subjects requiring cataract surgery were assigned to Bromfenac ophthalmic solution or placebo. Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery. In 2 of the 3 studies, bromfenac ophthalmic solution had statistically significant higher incidence of completely clearing inflammation (46-47% vs. 25-29%) and also had a statistically significant higher incidence of subjects that were pain free at day 1 post cataract surgery (83-89% vs. 51-71%)."],"pharmacokinetics":["12.3 Pharmacokinetics The plasma concentration of bromfenac following ocular administration of Bromfenac Ophthalmic Solution 0.09% in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans."],"adverse_reactions":["6 ADVERSE REACTIONS The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging) ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience The most commonly reported adverse experiences reported following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2-7% of patients. 6.2 Post-Marketing Experience The following events have been identified during post-marketing use of bromfenac ophthalmic solution 0.09% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution 0.09% or a combination of these factors, include corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown. [ see Warnings and Precautions (5) ]"],"contraindications":["4 CONTRAINDICATIONS None."],"mechanism_of_action":["12.1 Mechanism of Action Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. 12.3 Pharmacokinetics The plasma concentration of bromfenac following ocular administration of Bromfenac Ophthalmic Solution 0.09% in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans."],"indications_and_usage":["1 INDICATIONS AND USAGE Bromfenac Ophthalmic Solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. BROMFENAC is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Sulfite Allergic Reactions ( 5.1 ) Slow or Delayed Healing ( 5.2 ) Potential for cross-sensitivity ( 5.3 ) Increase bleeding of ocular tissues ( 5.4 ) Corneal effects including keratitis ( 5.5 ) Contact Lens Wear ( 5.6 ) 5.1 Sulfite Allergic Reactions Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. 5.2 Slow or Delayed Healing All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. 5.3 Potential for Cross-Sensitivity There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. 5.4 Increased Bleeding Time With some NSAIDs, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. 5.5 Keratitis and Corneal Reactions Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health. Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events. 5.6 Contact Lens Wear Bromfenac should not be administered while wearing contact lenses."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence. Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests. Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively)."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION 17.1 Slowed or Delayed Healing Patients should be advised of the possibility that slow or delayed healing may occur while using NSAIDs. 17.2 Sterility of Dropper Tip Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents. 17.3 Concomitant Use of Contact Lenses Contact lenses should not be worn during the use of this product. 17.4 Concomitant Topical Ocular Therapy If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart. Rx Only Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA Made in India. Manufactured by: Alembic Pharmaceuticals Limited Karakhadi - 391 450, Gujarat, India. Or Manufactured by: Gland Pharma Limited Hyderabad-500 043,INDIA. Revised: 01/2023"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery ( 2.1 ). 2.1 Recommended Dosing For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of bromfenac ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period. 2.2 Use with Other Topical Ophthalmic Medications Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart."],"spl_product_data_elements":["Bromfenac Ophthalmic Solution 0.09% Bromfenac Ophthalmic Solution 0.09% BROMFENAC SODIUM BROMFENAC BORIC ACID EDETATE DISODIUM POLYSORBATE 80 POVIDONE K30 SODIUM BORATE SODIUM SULFITE SODIUM HYDROXIDE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Topical ophthalmic solution: bromfenac 0.09%. Topical ophthalmic solution: bromfenac 0.09%"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Teratogenic Effects: Pregnancy Category C . Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post implantation loss. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided. 8.3 Nursing Mothers Caution should be exercised when bromfenac is administered to a nursing woman. 8.4 Pediatric Use Safety and efficacy in pediatric patients below the age of 18 have not been established. 8.5 Geriatric Use There is no evidence that the efficacy or safety profiles for bromfenac differ in patients 65 years of age and older compared to younger adult patients."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Bromfenac Ophthalmic Solution, 0.09% - Bottle label - Gland Pharma Limited Bromfenac Ophthalmic Solution, 0.09% - Carton label - Gland Pharma Limited Bromfenac Ophthalmic Solution, 0.09% - Bottle label - Alembic Pharmaceuticals Limited Bromfenac Ophthalmic Solution, 0.09% - Carton label - Alembic Pharmaceuticals Limited bromfenac-bott bromfenac-cart bromfenac-bottle-apl bromfenac-carton-apl"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence. Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests. Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively)."]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Anterior chamber inflammation","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Foreign body sensation","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Photophobia","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"5.5%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bromfenac ophthalmic solution","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:13:06.617736+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:13:32.226360+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:13:12.093110+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bromfenac ophthalmic solution","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:13:12.394786+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:05.513064+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:25.401815+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:05.513090+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1077/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:13:13.237778+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA210560","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:05.513094+00:00"}},"_dailymed":{"setId":"246e2110-6a2d-4e22-8e37-72d80796b9af","title":"BROMFENAC OPHTHALMIC SOLUTION (BROMFENAC SODIUM) SOLUTION/ DROPS [BAUSCH & LOMB AMERICAS INC.]"},"aiSummary":"Bromfenac ophthalmic solution, marketed by Bausch & Lomb Incorporated, is a postoperative treatment for inflammation and ocular pain following cataract surgery. The drug's key strength lies in its established market presence, supported by a key composition patent that remains in effect until 2028. The primary risk to consider is the potential increase in competition as the patent approaches expiration.","_scrapedAt":"2026-03-28T01:41:59.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T07:13:32.226475+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"bromfenac-ophthalmic-solution-postoperative-inflammation-and","name":"Postoperative inflammation and ocular pain after cataract surgery","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients who have undergone cataract surgery","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients who have undergone cataract surgery","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":"Inflammation Eye","enrollment":92},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT06130384","phase":"PHASE4","title":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2021-03-01","conditions":"Pain, Intravitreal Injection, Pain, Acute","enrollment":97},{"nctId":"NCT05107921","phase":"PHASE2","title":"Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2021-11-01","conditions":"Familial Exudative Vitreoretinopathies","enrollment":39},{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":"Intravitreal Injections, IVI","enrollment":46},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":"Cystoid Macular Edema Following Cataract Surgery","enrollment":90},{"nctId":"NCT01478555","phase":"PHASE2","title":"A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-01","conditions":"Dry Eye Disease","enrollment":""},{"nctId":"NCT05006898","phase":"PHASE1","title":"Compound to Control Presbyopia Symptoms","status":"COMPLETED","sponsor":"Optall Vision","startDate":"2020-06-01","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT05001243","phase":"PHASE1","title":"Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-10","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT00758784","phase":"PHASE2","title":"Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-08-13","conditions":"Dry Eye Disease","enrollment":38},{"nctId":"NCT01212471","phase":"PHASE3","title":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":840},{"nctId":"NCT03521791","phase":"PHASE4","title":"Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-12-13","conditions":"Pterygium, Ocular Pain, Ocular Inflammation","enrollment":166},{"nctId":"NCT01535443","phase":"PHASE1","title":"Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2011-09","conditions":"Inflammation, Cataract","enrollment":35},{"nctId":"NCT04022811","phase":"PHASE4","title":"Effect of Bromfenac on Pain Related to Pterygium Surgery","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-10","conditions":"Pterygium, Pain","enrollment":60},{"nctId":"NCT03886779","phase":"PHASE4","title":"Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2013-10-30","conditions":"Treatment of Ocular Inflammation Associated With Cataract Surgery","enrollment":57},{"nctId":"NCT02973880","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2017-10-15","conditions":"Cataract Extraction, Cataract","enrollment":180},{"nctId":"NCT01847638","phase":"NA","title":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","status":"COMPLETED","sponsor":"Melissa Toyos","startDate":"2013-04-01","conditions":"Cataract, Retinal Edema, Inflammation","enrollment":50},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT00438243","phase":"PHASE2","title":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-05","conditions":"Cystoid Macular Edema","enrollment":""},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":"Myopia","enrollment":20},{"nctId":"NCT02681679","phase":"NA","title":"Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":"Cataract","enrollment":60},{"nctId":"NCT00703781","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":126},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":"Vitreous Inflammation","enrollment":70},{"nctId":"NCT01367249","phase":"PHASE3","title":"Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":"Pain, Inflammation, Cataract","enrollment":440},{"nctId":"NCT00423007","phase":"PHASE3","title":"Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Allergic Conjunctivitis","enrollment":90},{"nctId":"NCT00198445","phase":"PHASE3","title":"Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2003-05","conditions":"Postoperative Complications, Cataract","enrollment":527},{"nctId":"NCT00585975","phase":"PHASE2","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":"Cataract Surgery","enrollment":568},{"nctId":"NCT00333918","phase":"PHASE3","title":"Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Pain, Inflammation","enrollment":522},{"nctId":"NCT00853970","phase":"PHASE3","title":"Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Pain, Inflammation","enrollment":299},{"nctId":"NCT00704418","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":156},{"nctId":"NCT00758199","phase":"PHASE4","title":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-07","conditions":"Cataracts","enrollment":49},{"nctId":"NCT00805233","phase":"PHASE2","title":"Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-12","conditions":"Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Cataracts","enrollment":200},{"nctId":"NCT00491166","phase":"PHASE1","title":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2007-06","conditions":"Diabetic Macular Edema","enrollment":10}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"EYE IRRITATION"},{"count":6,"reaction":"EYE PAIN"},{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"PRODUCT DOSE OMISSION ISSUE"},{"count":4,"reaction":"OFF LABEL USE"},{"count":4,"reaction":"PRODUCT PACKAGING QUANTITY ISSUE"},{"count":4,"reaction":"VISION BLURRED"},{"count":3,"reaction":"CYSTOID MACULAR OEDEMA"},{"count":3,"reaction":"EYE SWELLING"},{"count":3,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"}],"administration":{"route":"Ophthalmic"},"crossReferences":{"chemblId":"CHEMBL1077"},"_approvalHistory":[{"date":"20190621","type":"ORIG","sponsor":"ALEMBIC","applicationNumber":"ANDA210560"},{"date":"20240708","type":"ORIG","sponsor":"APOTEX","applicationNumber":"ANDA207334"},{"date":"20250218","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA203168"},{"date":"20151202","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA203168"},{"date":"20150701","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA203168"},{"date":"20130405","type":"ORIG","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA203168"}],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"bromfenac ophthalmic solution","genericName":"bromfenac ophthalmic solution","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T07:13:32.226475+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}